Drugs / Indobufen
Indobufen
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01232023 | Jan → Dec 2010 | — | Asan Medical Center | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00244426 | Dec 2000 → Apr 2008 | atrial fibrillation | Pfizer | Completed | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT06451198 | May 2025 → Dec 2028 expected | coronary artery disorder | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05105750 | Oct 2021 → Mar 2022 | coronary atherosclerosis | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT04129008 | Oct 2019 → Sep 2020 | coronary artery disorder, gastroesophageal reflux disease | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03871517 | Jun 2019 → Mar 2022 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03230851 | Aug 2017 → Jul 2018 | coronary atherosclerosis | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07089862 | Aug 2025 → Dec 2026 expected | brain aneurysm | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT04308551 | Dec 2024 → Dec 2026 | coronary artery disorder | Henan Institute of Cardiovascular Epidemiology | Withdrawn | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | indobufen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05105750 ↗ |
| Known as | Ibustrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1765292 ↗ |
| Known as | Indobufene | ChEMBL registry synonym — accepted as the source's own label CHEMBL1765292 ↗ |
| Known as | K-2930 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1765292 ↗ |
| Known as | K-3920 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1765292 ↗ |
| Action | Inhibit | “Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.” NCT03871517 ↗ |
| Modality | Small molecule | — CHEMBL1765292 ↗ |
| Route | Oral | “Single Oral Dose of” NCT01232023 ↗ |